Coya Therapeutics is monitored and covered by several boutique investment banks and specialized healthcare equity research firms on Wall Street. Prominent financial institutions providing regular ratings and price targets for the company include Roth Capital Partners, among other life science-focused brokerage analysts who issue periodic consensus updates and buy recommendations.